Williams Stuart K, Morris Marvin E, Kosnik Paul E, Lye Kevin D, Gentzkow Gary D, Ross Charles B, Dwevidi Amit J, Kleinert Leigh B
1 University of Louisville , Cardiovascular Innovation Institute, Louisville, Kentucky.
2 Tissue Genesis, LLC , Honolulu, Hawai'i.
Tissue Eng Part C Methods. 2017 Aug;23(8):497-504. doi: 10.1089/ten.TEC.2017.0105.
Adipose-derived stromal vascular fraction (SVF) cell populations are being evaluated for numerous clinical applications. The current study evaluated a point-of-care technology, the Tissue Genesis "TGI 1000" Cell Isolation System™, to perform an automated isolation of adipose-derived SVF cells to be used in the fabrication of a tissue-engineered vascular graft in the operating room. A total of seven patients were enrolled in this study and received femoral to tibial expanded polytetrafluoroethylene bypass grafts to treat peripheral arterial disease. Lipoaspiration of fat was performed on five patients, and the fat sample was processed immediately in the automated system in the operating room. The mean processing time, from the point of fat delivery into the instrument to removal of the SVF-containing syringe, was 70 min. The SVF cell population was evaluated for cell yield, cell viability, endotoxin levels, and microbial contamination. Samples of the SVF preparation were further subjected to microbiologic evaluation both microscopically before implantation of the graft and through a microbiologic screening using aerobic and anaerobic culture conditions. Mean cell yield was 1E5 cells per cc of fat, and endotoxin levels were below the FDA recognized standards. All SVF preparations were released for graft preparation, and the intimal surface of 90-cm-long grafts was pressure sodded with cells at a concentration of 2E5 cells/cm. The sodded grafts (n = 5) and control grafts (n = 2) were immediately implanted and graft patency assessed for 1 year. One year patency was 60% for sodded grafts and 50% for control grafts. Automated preparation of autologous adipose-derived SVF cells for immediate use to create cellular linings on vascular grafts is feasible and safe.
脂肪来源的基质血管成分(SVF)细胞群正被评估用于众多临床应用。本研究评估了一种床旁即时检测技术,即组织创生公司的“TGI 1000”细胞分离系统™,以在手术室中自动分离脂肪来源的SVF细胞,用于制造组织工程血管移植物。本研究共纳入7例患者,他们接受了股-胫段膨体聚四氟乙烯旁路移植术以治疗外周动脉疾病。对5例患者进行了脂肪抽吸,脂肪样本在手术室的自动系统中立即进行处理。从脂肪送入仪器到取出含有SVF的注射器的平均处理时间为70分钟。对SVF细胞群进行了细胞产量、细胞活力、内毒素水平和微生物污染评估。在移植物植入前,对SVF制剂样本进行显微镜下微生物学评估,并通过需氧和厌氧培养条件进行微生物筛查。平均细胞产量为每立方厘米脂肪1×10⁵个细胞,内毒素水平低于美国食品药品监督管理局认可的标准。所有SVF制剂均被放行用于移植物制备,90厘米长的移植物内膜表面以2×10⁵个细胞/厘米的浓度进行细胞接种。接种后的移植物(n = 5)和对照移植物(n = 2)立即植入,并评估移植物通畅情况1年。接种移植物的1年通畅率为60%,对照移植物为50%。自动制备自体脂肪来源的SVF细胞以立即用于在血管移植物上创建细胞内衬是可行且安全的。